Market Access Today’s Post

🔬💊 Revolutionizing Pancreatic Cancer Treatment: The Power of Patient-Derived Organoids Pancreatic cancer poses a formidable challenge in the medical world, having the highest mortality rate among major cancers. But what if miniature models of a patient's tumor could change the game? Enter patient-derived organoids, a cutting-edge biotechnology offering a personalized approach to treatment. Researchers at the Salk Institute recently shed light on the reliability of these organoids in mimicking pancreatic tumors. Their study, published in JCI Insight, revealed that the choice of extracellular matrix—the scaffold for growing these organoids—didn't significantly alter gene expression or drug responses. However, one brand did accelerate organoid growth, an advantage for the urgency in pancreatic cancer treatment. Dr. Dannielle Engle, the study's senior author, emphasizes the importance of personalized medicine. With organoids, clinicians gain a predictive model to tailor treatments effectively, sparing patients from the "guessing game" of traditional approaches. While variations in culture media can influence organoid behavior, differences in extracellular matrices had minimal impact. This discovery strengthens confidence in organoid technology's accuracy and reliability for evaluating patient drug responses. With continued optimization and validation, these organoids hold promise in improving patient outcomes.   « Together, we're inching closer to a future where pancreatic cancer is no longer a death sentence » For further information, check the following paper.  https://lnkd.in/eKP-wwJ4

#ScientificSaturday 🔬Gefitinib ― is a targeted cancer therapy drug, specifically a tyrosine kinase inhibitor, used primarily to treat non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. By inhibiting EGFR, gefitinib helps slow or stop the growth of cancer cells that overexpress this protein. It is administered orally and is most effective in patients whose tumors have specific EGFR mutations, determined through genetic testing. While gefitinib has improved treatment outcomes for some patients, it can also cause side effects such as skin reactions and diarrhea, and its effectiveness may diminish over time due to drug resistance. ❗This study explores the mechanisms behind gefitinib resistance in lung adenocarcinoma (LUAD) patients with EGFR mutations, focusing on the role of ferroptosis, a form of programmed cell death. The researchers discovered that gefitinib resistance in EGFR-mutated LUAD cells is partly due to the inhibition of ferroptosis, with the aldo-keto reductase family 1 member C1 (AKR1C1) identified as significantly upregulated in resistant cell strains, correlating with poorer patient outcomes. Further, they revealed that AKR1C1 upregulation is mediated by the decreased expression of miR-338-3p and the involvement of the long non-coding RNA NEAT1_1, which sponges miR-338-3p, neutralizing its suppression of AKR1C1. To read what else this study uncovered, click the link below. BioPharma Services Inc. has previously completed multiple clinical trials on Gefitinib. Trust our world-class Pharmacokinetic team with your next #Phase1, BA/BE or Human Abuse Liability (#HAL) drug development project. Read the full blog here: 👇 https://hubs.li/Q02qqyMT0 Discover our Services: 👇 https://hubs.li/Q02qqDKs0 #clinicalresearch #biopharma #drugdevelopment #drugresearch #cro #clinicaltrials

Genprex, Inc. Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC). "We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer." https://lnkd.in/eSwgXndy

𝗨𝗻𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗼𝗳 𝗩𝗮𝗹𝗲𝗺𝗲𝘁𝗼𝘀𝘁𝗮𝘁: 𝗔 𝗡𝗲𝘄 𝗛𝗼𝗽𝗲 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Researchers identified the mechanism of the cancer drug valemetostat and established its efficacy in treating adult T-cell leukemia/lymphoma.   👉 The development of epigenetic therapeutics has promise for cancer treatment. One promising drug is valemetostat. Essentially, valemetostat prevents the methylation of histone H3 by inhibiting the histone-modifying enzymes EZH1 and EZH2. 👉 A study published in 𝘕𝘢𝘵𝘶𝘳𝘦 aimed to better understand the mechanism and efficacy of valemetostat. Researchers conducted single-cell gene sequencing on samples taken from adults given valemetostat to treat Tcell-leukaemia/lymphoma, a rare type of blood cancer. The study revealed that the drug leads to the reprogramming of the cancer epigenome, abolishing the highly condensed chromatin structure formed by the tri-methyl-histone H3. This results in several tumor suppressor genes becoming accessible for expression and thereby the inhibItion of tumor cell growth. This study represents a significant step forward in the field of epigenetic cancer treatments, a hope for more personalized treatment.    #cancerresearch #drug #lymphoma #epigenome #epigenetics #medicine #biology https://lnkd.in/eDAxKJj5

Source: Journal of pharmaceutical and biomedical analysis A study found distinct differences in the plasma molecular profiles of early-onset and late-onset colorectal cancer patients. Using metabolomics and lipidomics analyses, the study identified specific metabolites and lipids that were altered in the colorectal cancer group. The analysis also revealed that early-onset colorectal cancer patients had unique metabolomic and lipidomic profiles compared to late-onset patients. Gene expression data further supported these distinctions. The findings provide insights into the development mechanisms of early-onset colorectal cancer and potential plasma biomarkers for diagnosis.

Annexins and cancer Antibody to annexin A1 (AnxA1) halts cancer cell proliferation in vitro and in vivo. Cell cycle arrested in G1 phase. Already established that Knockout of AnxA2 gene targets metastasis by reducing membrane repair of cells in the circulation. Annexin “therapies” look more and more interesting .. #annexin #AnxA1 #proliferation #metastasis #cellcycle #therapies

🎉Pfizer's TALZENNA® Receives Novel EU #Approval for Prostate Cancer Treatment! 🎉 ℹ Pfizer's oral PARP inhibitor, TALZENNA®, in combination with XTANDI®, has been approved by the #europeancommission for metastatic castration-resistant prostate cancer (mCRPC). This marks the #first and only PARP inhibitor licensed in the EU for use with XTANDI for patients with mCRPC, with or without gene mutations. The approval is based on data from the Phase III TALAPRO-2 trial, which showed that TALZENNA plus XTANDI reduced the risk of disease progression or death by 37 percent versus placebo plus XTANDI. The #combination offers an effective #treatment that addresses disease progression in patients with or without any specific gene mutation. 💡 This significant advancement underscores Pfizer's #commitment to providing #innovative treatments for patients with prostate #cancer. #Pfizer #TALZENNA #XTANDI #ProstateCancer #innovation #EUApproval #medicaladvancements #cancertreatment #SymmetricTraining

The management of lung cancer (LC) requires the analysis of a diverse spectrum of molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF and MET oncogenes, KRAS G12C substitutions, and ALK, ROS1, RET and NTRK1-3 gene fusions. Administration of immune checkpoint inhibitors (ICIs) is based on the immunohistochemical (IHC) analysis of PD-L1 expression and determination of tumor mutation burden (TMB). Clinical characteristics of the patients, particularly age, gender and smoking history, significantly influence the probability of finding the above targets: for example, LC in young patients is characterized by high frequency of kinase gene rearrangements, while heavy smokers often have KRAS G12C mutations and/or high TMB. Proper selection of first-line therapy influences overall treatment outcomes, therefore, the majority of these tests need to be completed within no more than 10 working days. Activating events in MAPK signaling pathway are mutually exclusive, hence, fast single-gene testing remains an option for some laboratories. RNA next-generation sequencing (NGS) is capable of detecting the entire repertoire of druggable gene alterations, therefore it is gradually becoming a dominating technology in LC molecular diagnosis. 🎬 Current status of molecular diagnostics for lung cancer 📝 Authors: Evgeny N. Imyanitov *, Elena V. Preobrazhenskaya, Sergey V. Orlov 📚 This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer 👨⚕️Guest Editor: Prof. Dr. Alessandro Morabito and Dr. Edoardo Mercadante, MD, PhD 🏃♂️ Welcome to read, forward, and share the article! https://lnkd.in/gQi54-BK 📄 PDF: https://lnkd.in/gXBYEZy8 #LungCancer #Mutations #Fusions #PredictiveMarkers #Therapy

📰News from the field: FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma The FDA has just approved #Tecelra, the first T-cell receptor (TCR) therapy for synovial #sarcoma. This novel treatment brings hope to patients who have not responded to standard care. #Tecelra targets the MAGE-A4 #protein within #CancerCells, offering a promising new approach to fighting this rare cancer. 🤔 Curious about how Tecelra works and its potential impact? 🔗Read more: https://bit.ly/4e8cgaZ #lymphoma #cancerresearch #cancertreatment #autoimmunediseases #lymphocyteengineering #tecelra #adaptimmune #fdaapproval #genetherapy #cancer #cgtmarket #marketresearch #synovialsarcoma #regenerativemedicine #orphandrug #fda #regulatoryapproval SPIMA Therapeutics Pharmaceutical Innovation Advisory-FZE Gene Tech Laboratories Helplogic Consultants ScirosBio